Valeant Bids $418M To Keep Top Spot In Obagi Bidding War
Canadian drugmaker Valeant Pharmaceuticals International Inc. increased its bid for Obagi Medical Products Inc. to about $418 million Wednesday, revising its acquisition agreement after an offer by a German competitor threatened to...To view the full article, register now.
Already a subscriber? Click here to view full article